The Asia Pacific Emphysema Treatment Market would witness market growth of 7.1% CAGR during the forecast period (2022-2028).
The alleviation of symptoms, the prevention of consequences, and the slowing down of the evolution of the illness are the objectives of treatment for emphysema. Patients diagnosed with emphysema should also make every effort to kick the habit of smoking as soon as possible since continuing to do so will only exacerbate the condition of their lungs.
Pulmonary rehabilitation is an essential component of the therapy for emphysema. This component involves education, dietary counseling, the learning of unique breathing methods, assistance with stopping smoking, and the beginning of an exercise routine. Emphysema patients often have physical limitations, so they may avoid any activity requiring them to move about. However, regular physical exercise is one of the best ways for a patient to enhance their health and well-being.
India is one of the nations with the highest population density, and it has a significant proportion of its population at least 60 years old. And it is anticipated that the percentage of elderly people living in India will continue to climb. According to the projections made by the country's government, the percentage will climb from 7.5% in 2010 to 11.1% in 2025.
China has one of the populations that is becoming older at one of the quickest rates in the world. It is anticipated that by the year 2040, the proportion of China's population that is over 60 years old will reach 28 percent, thanks to rising life expectancy and falling birth rates. As individuals live longer, their risk of developing chronic diseases like emphysema increases. This is especially true for older people. Because of this, it is anticipated that the market for emphysema treatments will grow in the area as the elderly population continues to grow.
The China market dominated the Asia Pacific Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $394.2 million by 2028. The Japan market is estimated to grow at a CAGR of 6.4% during (2022 - 2028). Additionally, The India market would exhibit a CAGR of 8% during (2022 - 2028).
Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Emphysema Treatment Market is Projected to reach USD 6.05 Billion by 2028, at a CAGR of 6.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
By Medication Type
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
